Amneal Launches Its Generic Lanreotide Immediately While the Brand Still Posts Nearly a Billion in US Sales
FDA approved Amneal Pharmaceuticals’ lanreotide injection (120 mg/0.5 mL single-dose prefilled syringe), referencing Ipsen’s Somatuline Depot and carrying Competitive Generic Therapy designation. Amneal says it launched immediately. Somatuline Depot had $983M in US sales (12 months ended July 2026).
How this was made
The 30-second read
Why it matters
The approval adds a third lanreotide option in the U.S., but pricing impact is uncertain because the drug is administered in clinical settings and billed under medical benefits.
Market read
First‑time FDA approval of a generic injectable; may affect specialty injectable pricing and market dynamics.
What to watch
Potential supply‑chain resilience benefits from a third manufacturer could be valued by providers.
Background
Amneal Pharmaceuticals received FDA approval for a 120 mg/0.5 mL lanreotide prefilled syringe, referencing Ipsen's Somatuline Depot, and launched it immediately.
Ticker impact
FDA approved Amneal's generic lanreotide injection and launched it immediately, adding a new competitor to the $983M U.S. brand market.
Slight upward pressure if formulary inclusion expands; otherwise limited movement.
The approval is new and material, but the injectable is billed under medical benefits and substitution is slow, reducing immediate price volatility.
Market effects
Adds competitive pressure in the specialty injectable market, may influence pricing dynamics for other long‑acting peptide drugs.
U.S. specialty pharma market sees a new generic entrant; limited immediate effect on broader market.
Highlights FDA's competitive generic therapy pathway, relevant for global pharma companies pursuing similar approvals.
Counterpoint
The new generic may not translate into price cuts or market share gains due to medical‑benefit billing and payer contracts.
Key entities
- CompanyAmneal Pharmaceuticals
US‑listed specialty pharma launching generic lanreotide.
- CompanyIpsen
Owner of the branded Somatuline Depot.
- CompanyCipla
Previous generic lanreotide entrant.
